Bernstein raised the firm’s price target on Medtronic (MDT) to $97 from $96 and keeps an Outperform rating on the shares. The firm notes revenue growth has been more consistent, and new launches can add upside to growth. With low expectations and a valuation multiple that is low relative to history, Bernstein sees more upside than downside for Medtronic over the next twelve months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $93 from $96 at Baird
- Medtronic price target lowered to $98 from $106 at Wells Fargo
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Morning Movers: Walmart jumps following quarterly results